Another paper using RVX-2135 in pre-clinical cancer studies came out recently entitled "BET bromodomain inhibitors synergize with ATR inhibitors in melanoma in melanoma." This adds to some other literature published/presented on RVX-2135 including this 2013 AACR meeting abstract and this 2014 PNAS paper. I'm posting this on the Zenith board because it is focuses on cancer. However, the RVX-2135 molecule belongs to Resverlogix now if I understand the flow of IP correctly. Interestingly, one paper describes RVX-2135 as: "RVX-2135 is based on the same chemical scaffold as RVX-208. Although it preferentially binds BD2, it is a pan-BET protein inhibitor, with anti-tumour activity in AML and murine lymphoma." I wonder if this molecule has any clinical promise, or if ZEN-3694 was found to be a superior molecule that does everything RVX-2135 does and more?

BearDownAZ